CTNM — Contineum Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855175 ·
Last close
$15.49
Market Cap
$510.53M
52W High
$16.91
52W Low
$11.17
ADV30
415,123
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -17,428,000 | -15,154,000 | 250,367,000 | 14,711,000 | 10,707,000 |
| Mar 2026 | 0 | — | -16,904,000 | -14,456,000 | 261,349,000 | 20,158,000 | 11,308,000 |
| Dec 2025 | 0 | — | -17,115,000 | -15,156,000 | 276,642,000 | 75,603,000 | 15,653,000 |
| Sep 2025 | 0 | — | -14,932,000 | -12,792,000 | 190,847,000 | 42,633,000 | 10,377,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-53,006,000
Investing CF
$-66,966,000
Financing CF
$113,899,000
CapEx
$-458,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-177,380,000
Inventory
—
Receivables
—
ST Investments
$187,293,000
EBIT TTM
$-68,059,000
Pretax Income TTM
$-59,978,000
Interest Exp TTM
$0
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -68,059,000 | -59,978,000 | 276,642,000 | 15,653,000 | — | -55,312,000 |
| Dec 2024 | 0 | -50,894,000 | -42,258,000 | 212,847,000 | 14,781,000 | — | -32,845,000 |
| Dec 2023 | 50,000,000 | 16,077,000 | 22,720,000 | 130,386,000 | 198,322,000 | — | 19,349,000 |
| Dec 2022 | 0 | -22,720,000 | -24,253,000 | 50,636,000 | 143,848,000 | — | -20,121,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VSTM | Verastem, Inc. | $509.67M | $5.80 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $509.43M | $5.13 | — |
| ARVN | ARVINAS, INC. | $518.11M | $8.03 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $497.61M | $25.11 | — |
| SLN | Silence Therapeutics plc | $495.49M | $10.49 | — |
News headlines (Yahoo Finance, 1h cache)
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
2026-07-30 20:05 · Yahoo
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
2026-07-09 16:00 · Yahoo
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
2026-06-30 20:05 · Yahoo
Are Medical Stocks Lagging Adagene (ADAG) This Year?
2026-06-02 13:40 · Yahoo
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
2026-05-25 13:55 · Yahoo
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
2026-05-22 12:03 · Yahoo
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-05-15 13:40 · Yahoo
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
2026-05-08 13:55 · Yahoo
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth
2026-04-19 12:03 · Yahoo
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
2026-03-15 01:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.